Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 59

1.

PAF promotes stemness and radioresistance of glioma stem cells.

Ong DST, Hu B, Ho YW, Sauvé CG, Bristow CA, Wang Q, Multani AS, Chen P, Nezi L, Jiang S, Gorman CE, Monasterio MM, Koul D, Marchesini M, Colla S, Jin EJ, Sulman EP, Spring DJ, Yung WA, Verhaak RGW, Chin L, Wang YA, DePinho RA.

Proc Natl Acad Sci U S A. 2017 Oct 24;114(43):E9086-E9095. doi: 10.1073/pnas.1708122114. Epub 2017 Oct 9.

2.

Activation of WEE1 confers resistance to PI3K inhibition in glioblastoma.

Wu S, Wang S, Gao F, Li L, Zheng S, Yung WKA, Koul D.

Neuro Oncol. 2018 Jan 10;20(1):78-91. doi: 10.1093/neuonc/nox128.

PMID:
29016926
3.

APOBEC3G acts as a therapeutic target in mesenchymal gliomas by sensitizing cells to radiation-induced cell death.

Wang Y, Wu S, Zheng S, Wang S, Wali A, Ezhilarasan R, Sulman EP, Koul D, Alfred Yung WK.

Oncotarget. 2017 Apr 21;8(33):54285-54296. doi: 10.18632/oncotarget.17348. eCollection 2017 Aug 15.

4.

Preclinical therapeutic efficacy of a novel blood-brain barrier-penetrant dual PI3K/mTOR inhibitor with preferential response in PI3K/PTEN mutant glioma.

Koul D, Wang S, Wu S, Saito N, Zheng S, Gao F, Kaul I, Setoguchi M, Nakayama K, Koyama K, Shiose Y, Sulman EP, Hirota Y, Yung WKA.

Oncotarget. 2017 Mar 28;8(13):21741-21753. doi: 10.18632/oncotarget.15566.

5.

MSK1-Mediated β-Catenin Phosphorylation Confers Resistance to PI3K/mTOR Inhibitors in Glioblastoma.

Wu S, Wang S, Zheng S, Verhaak R, Koul D, Yung WK.

Mol Cancer Ther. 2016 Jul;15(7):1656-68. doi: 10.1158/1535-7163.MCT-15-0857. Epub 2016 Apr 22.

6.

Retraction: Novel HSP90 inhibitor NVP-HSP990 targets cell-cycle regulators to ablate Olig 2-positive glioma tumor-initiating cells.

Koul D, Yao J, Wan S, Yuan Y, Sulman E, Lang F, Yung WK, Colman H.

Cancer Res. 2014 Nov 15;74(22):6731-2. doi: 10.1158/0008-5472.CAN-14-2966. No abstract available.

7.

Importance of obtaining lumbar puncture in neonates with late onset septicemia a hospital based observational study from north-west India.

Kaul V, Harish R, Ganjoo S, Mahajan B, Raina SK, Koul D.

J Clin Neonatol. 2013 Apr;2(2):83-7. doi: 10.4103/2249-4847.116407.

8.

A high Notch pathway activation predicts response to γ secretase inhibitors in proneural subtype of glioma tumor-initiating cells.

Saito N, Fu J, Zheng S, Yao J, Wang S, Liu DD, Yuan Y, Sulman EP, Lang FF, Colman H, Verhaak RG, Yung WK, Koul D.

Stem Cells. 2014 Jan;32(1):301-12. doi: 10.1002/stem.1528.

9.

A survey of intragenic breakpoints in glioblastoma identifies a distinct subset associated with poor survival.

Zheng S, Fu J, Vegesna R, Mao Y, Heathcock LE, Torres-Garcia W, Ezhilarasan R, Wang S, McKenna A, Chin L, Brennan CW, Yung WK, Weinstein JN, Aldape KD, Sulman EP, Chen K, Koul D, Verhaak RG.

Genes Dev. 2013 Jul 1;27(13):1462-72. doi: 10.1101/gad.213686.113. Epub 2013 Jun 24.

10.

Identification of prognostic gene signatures of glioblastoma: a study based on TCGA data analysis.

Kim YW, Koul D, Kim SH, Lucio-Eterovic AK, Freire PR, Yao J, Wang J, Almeida JS, Aldape K, Yung WK.

Neuro Oncol. 2013 Jul;15(7):829-39. doi: 10.1093/neuonc/not024. Epub 2013 Mar 15.

11.

Novel HSP90 inhibitor NVP-HSP990 targets cell-cycle regulators to ablate Olig2-positive glioma tumor-initiating cells.

Fu J, Koul D, Yao J, Wang S, Yuan Y, Colman H, Sulman EP, Lang FF, Yung WK.

Cancer Res. 2013 May 15;73(10):3062-74. doi: 10.1158/0008-5472.CAN-12-2033. Epub 2013 Mar 14. Retraction in: Koul D, Yao J, Wan S, Yuan Y, Sulman E, Lang F, Yung WK, Colman H. Cancer Res. 2014 Nov 15;74(22):6731-2.

12.

Antitumor activity of NVP-BKM120--a selective pan class I PI3 kinase inhibitor showed differential forms of cell death based on p53 status of glioma cells.

Koul D, Fu J, Shen R, LaFortune TA, Wang S, Tiao N, Kim YW, Liu JL, Ramnarian D, Yuan Y, Garcia-Echevrria C, Maira SM, Yung WK.

Clin Cancer Res. 2012 Jan 1;18(1):184-95. doi: 10.1158/1078-0432.CCR-11-1558. Epub 2011 Nov 7.

13.

An integrated in vitro and in vivo high-throughput screen identifies treatment leads for ependymoma.

Atkinson JM, Shelat AA, Carcaboso AM, Kranenburg TA, Arnold LA, Boulos N, Wright K, Johnson RA, Poppleton H, Mohankumar KM, Féau C, Phoenix T, Gibson P, Zhu L, Tong Y, Eden C, Ellison DW, Priebe W, Koul D, Yung WK, Gajjar A, Stewart CF, Guy RK, Gilbertson RJ.

Cancer Cell. 2011 Sep 13;20(3):384-99. doi: 10.1016/j.ccr.2011.08.013.

14.

Tissue removal by ultrasound evaluation (the TRUE study): the Jetstream G2 system post-market peripheral vascular IVUS study.

Singh T, Koul D, Szpunar S, Torey J, Dhabuwala J, Saigh L, Pires LA, Davis T.

J Invasive Cardiol. 2011 Jul;23(7):269-73.

15.

Establishment and characterization of clinically relevant models of ependymoma: a true challenge for targeted therapy.

Guan S, Shen R, Lafortune T, Tiao N, Houghton P, Yung WK, Koul D.

Neuro Oncol. 2011 Jul;13(7):748-58. doi: 10.1093/neuonc/nor037. Epub 2011 Jun 8.

16.

Induction of MUC5AC mucin by conjugated bile acids in the esophagus involves the phosphatidylinositol 3-kinase/protein kinase C/activator protein-1 pathway.

Song S, Byrd JC, Guha S, Liu KF, Koul D, Bresalier RS.

Cancer. 2011 Jun 1;117(11):2386-97. doi: 10.1002/cncr.25796. Epub 2010 Dec 14.

17.

Identification of novel synergistic targets for rational drug combinations with PI3 kinase inhibitors using siRNA synthetic lethality screening against GBM.

Kim YW, Liu TJ, Koul D, Tiao N, Feroze AH, Wang J, Powis G, Yung WK.

Neuro Oncol. 2011 Apr;13(4):367-75. doi: 10.1093/neuonc/nor012.

18.

Combined action of the dinuclear platinum compound BBR3610 with the PI3-K inhibitor PX-866 in glioblastoma.

Gwak HS, Shingu T, Chumbalkar V, Hwang YH, DeJournett R, Latha K, Koul D, Alfred Yung WK, Powis G, Farrell NP, Bögler O.

Int J Cancer. 2011 Feb 15;128(4):787-96. doi: 10.1002/ijc.25394.

19.

Fulminant giant cell myocarditis and cardiogenic shock: an unusual presentation of malignant thymoma.

Koul D, Kanwar M, Jefic D, Kolluru A, Singh T, Dhar S, Kumar P, Cohen G.

Cardiol Res Pract. 2010;2010:185896. doi: 10.4061/2010/185896. Epub 2010 May 4.

20.

Cellular and in vivo activity of a novel PI3K inhibitor, PX-866, against human glioblastoma.

Koul D, Shen R, Kim YW, Kondo Y, Lu Y, Bankson J, Ronen SM, Kirkpatrick DL, Powis G, Yung WK.

Neuro Oncol. 2010 Jun;12(6):559-69. doi: 10.1093/neuonc/nop058. Epub 2010 Feb 15.

21.

Acute left ventricular remodeling after myocardial infarction on transthoracic echocardiography: a case series.

Koul D, Bess R, Rehan A, Cohen G.

J Am Soc Echocardiogr. 2009 Nov;22(11):1309.e1-5. doi: 10.1016/j.echo.2009.05.016.

PMID:
19883877
22.

NVP-BEZ235, a novel dual phosphatidylinositol 3-kinase/mammalian target of rapamycin inhibitor, elicits multifaceted antitumor activities in human gliomas.

Liu TJ, Koul D, LaFortune T, Tiao N, Shen RJ, Maira SM, Garcia-Echevrria C, Yung WK.

Mol Cancer Ther. 2009 Aug;8(8):2204-10. doi: 10.1158/1535-7163.MCT-09-0160. Epub 2009 Aug 11.

23.

Current concepts and management strategies in atrial flutter.

Dhar S, Lidhoo P, Koul D, Dhar S, Bakhshi M, Deger FT.

South Med J. 2009 Sep;102(9):917-22. doi: 10.1097/SMJ.0b013e3181b0f4b8. Review.

PMID:
19668035
24.

Exploratory analysis of the copy number alterations in glioblastoma multiforme.

Freire P, Vilela M, Deus H, Kim YW, Koul D, Colman H, Aldape KD, Bogler O, Yung WK, Coombes K, Mills GB, Vasconcelos AT, Almeida JS.

PLoS One. 2008;3(12):e4076. doi: 10.1371/journal.pone.0004076. Epub 2008 Dec 30.

25.

PTEN signaling pathways in glioblastoma.

Koul D.

Cancer Biol Ther. 2008 Sep;7(9):1321-5. Epub 2008 Sep 8. Review.

PMID:
18836294
26.

Current concepts in diastolic heart failure.

Dhar S, Koul D, D'Alonzo GE Jr.

J Am Osteopath Assoc. 2008 Apr;108(4):203-9. Review.

PMID:
18443028
27.

Tissue transglutaminase regulates focal adhesion kinase/AKT activation by modulating PTEN expression in pancreatic cancer cells.

Verma A, Guha S, Wang H, Fok JY, Koul D, Abbruzzese J, Mehta K.

Clin Cancer Res. 2008 Apr 1;14(7):1997-2005. doi: 10.1158/1078-0432.CCR-07-1533.

28.

Erythropoietin: new horizon in cardiovascular medicine.

Koul D, Dhar S, Chen-Scarabelli C, Guglin M, Scarabelli TM.

Recent Pat Cardiovasc Drug Discov. 2007 Jan;2(1):5-12. Review.

PMID:
18221097
29.

Transient left ventricular apical ballooning syndrome caused by abrupt metoprolol withdrawal.

Jefic D, Koul D, Boguszewski A, Martini W.

Int J Cardiol. 2008 Dec 17;131(1):e35-7. Epub 2007 Oct 22.

PMID:
17949833
30.

Transient apical ballooning: sheep in wolves' garb.

Dhar S, Koul D, Subramanian S, Bakhshi M.

Cardiol Rev. 2007 May-Jun;15(3):150-3. Review.

PMID:
17438381
31.

PTEN down regulates AP-1 and targets c-fos in human glioma cells via PI3-kinase/Akt pathway.

Koul D, Shen R, Shishodia S, Takada Y, Bhat KP, Reddy SA, Aggarwal BB, Yung WK.

Mol Cell Biochem. 2007 Jun;300(1-2):77-87. Epub 2007 Jan 18.

PMID:
17235455
32.

PTEN enhances TNF-induced apoptosis through modulation of nuclear factor-kappaB signaling pathway in human glioma cells.

Koul D, Takada Y, Shen R, Aggarwal BB, Yung WK.

Biochem Biophys Res Commun. 2006 Nov 17;350(2):463-71. Epub 2006 Sep 25.

33.

Cardiovascular effects of erythropoietin: anemia and beyond.

Guglin ME, Koul D.

Cardiol Rev. 2006 Jul-Aug;14(4):200-4. Review.

PMID:
16788333
34.

Inhibition of Akt survival pathway by a small-molecule inhibitor in human glioblastoma.

Koul D, Shen R, Bergh S, Sheng X, Shishodia S, Lafortune TA, Lu Y, de Groot JF, Mills GB, Yung WK.

Mol Cancer Ther. 2006 Mar;5(3):637-44.

35.
36.

Targeting integrin-linked kinase inhibits Akt signaling pathways and decreases tumor progression of human glioblastoma.

Koul D, Shen R, Bergh S, Lu Y, de Groot JF, Liu TJ, Mills GB, Yung WK.

Mol Cancer Ther. 2005 Nov;4(11):1681-8.

37.

Se-methylselenocysteine inhibits phosphatidylinositol 3-kinase activity of mouse mammary epithelial tumor cells in vitro.

Unni E, Koul D, Yung WK, Sinha R.

Breast Cancer Res. 2005;7(5):R699-707. Epub 2005 Jul 6.

38.
39.

Integrated array-comparative genomic hybridization and expression array profiles identify clinically relevant molecular subtypes of glioblastoma.

Nigro JM, Misra A, Zhang L, Smirnov I, Colman H, Griffin C, Ozburn N, Chen M, Pan E, Koul D, Yung WK, Feuerstein BG, Aldape KD.

Cancer Res. 2005 Mar 1;65(5):1678-86.

40.

Prognostic significance of tissue transglutaminase in drug resistant and metastatic breast cancer.

Mehta K, Fok J, Miller FR, Koul D, Sahin AA.

Clin Cancer Res. 2004 Dec 1;10(23):8068-76.

41.

Up-regulation of Flotillin-2 is associated with melanoma progression and modulates expression of the thrombin receptor protease activated receptor 1.

Hazarika P, McCarty MF, Prieto VG, George S, Babu D, Koul D, Bar-Eli M, Duvic M.

Cancer Res. 2004 Oct 15;64(20):7361-9.

43.

Differential activation of the Fas/CD95 pathway by Ad-p53 in human gliomas.

Cerrato JA, Khan T, Koul D, Lang FF, Conrad CA, Yung WK, Liu TJ.

Int J Oncol. 2004 Feb;24(2):409-17.

PMID:
14719118
44.

Src family protein-tyrosine kinases alter the function of PTEN to regulate phosphatidylinositol 3-kinase/AKT cascades.

Lu Y, Yu Q, Liu JH, Zhang J, Wang H, Koul D, McMurray JS, Fang X, Yung WK, Siminovitch KA, Mills GB.

J Biol Chem. 2003 Oct 10;278(41):40057-66. Epub 2003 Jul 17.

45.

MMAC/PTEN tumor suppressor gene regulates vascular endothelial growth factor-mediated angiogenesis in prostate cancer.

Koul D, Shen R, Garyali A, Ke LD, Liu TJ, Yung WK.

Int J Oncol. 2002 Sep;21(3):469-75.

PMID:
12168088
46.

Motif analysis of the tumor suppressor gene MMAC/PTEN identifies tyrosines critical for tumor suppression and lipid phosphatase activity.

Koul D, Jasser SA, Lu Y, Davies MA, Shen R, Shi Y, Mills GB, Yung WK.

Oncogene. 2002 Apr 4;21(15):2357-64.

47.

Promoter analysis of tumor suppressor gene PTEN: identification of minimum promoter region.

Sheng X, Koul D, Liu JL, Liu TJ, Yung WK.

Biochem Biophys Res Commun. 2002 Mar 29;292(2):422-6.

PMID:
11906179
48.

Suppression of matrix metalloproteinase-2 gene expression and invasion in human glioma cells by MMAC/PTEN.

Koul D, Parthasarathy R, Shen R, Davies MA, Jasser SA, Chintala SK, Rao JS, Sun Y, Benvenisite EN, Liu TJ, Yung WK.

Oncogene. 2001 Oct 11;20(46):6669-78.

49.

Transfer of E2F-1 to human glioma cells results in transcriptional up-regulation of Bcl-2.

Gomez-Manzano C, Mitlianga P, Fueyo J, Lee HY, Hu M, Spurgers KB, Glass TL, Koul D, Liu TJ, McDonnell TJ, Yung WK.

Cancer Res. 2001 Sep 15;61(18):6693-7.

50.

Tumor suppressor MMAC/PTEN inhibits cytokine-induced NFkappaB activation without interfering with the IkappaB degradation pathway.

Koul D, Yao Y, Abbruzzese JL, Yung WK, Reddy SA.

J Biol Chem. 2001 Apr 6;276(14):11402-8. Epub 2001 Jan 12.

Supplemental Content

Support Center